BOSTON, Aug. 4, 2026
CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for the treatment of Dementia with Lewy Bodies (DLB). The designation is intended to accelerate regulatory review and patient access for innovative medicines addressing serious unmet medical needs. The award recognizes neflamapimod’s potential to become a transformative therapy for DLB, a progressive neurodegenerative disorder with no approved treatments in the United States or European Union. Through ILAP, CervoMed will receive early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health Service (NHS), and health technology assessment organizations as it prepares for Phase 3 development.
Innovation Passport Supports Accelerated Regulatory Development
The Innovation Passport provides CervoMed with access to the UK’s integrated regulatory framework, enabling ongoing collaboration with the MHRA, NHS, the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and the Department of Health Northern Ireland. The program offers priority regulatory support, clinical trial guidance, and coordinated health technology assessment planning designed to shorten development timelines and improve patient access to promising therapies. CervoMed plans to leverage the designation while preparing for its anticipated Phase 3 clinical trial in DLB.
Clinical Data Continue to Support Neflamapimod Development
Neflamapimod is an investigational oral small-molecule inhibitor of the p38 MAP kinase alpha pathway, targeting neuroinflammation and synaptic dysfunction associated with neurodegenerative diseases. Across Phase 1 and Phase 2 clinical studies involving more than 800 participants, the therapy has demonstrated a favorable tolerability profile together with encouraging efficacy signals. In the 91-patient Phase 2a AscenD-LB trial, neflamapimod significantly improved dementia severity and functional mobility in patients with DLB. The subsequent 159-patient Phase 2b RewinD-LB study further demonstrated improvements in cognitive and functional outcomes while also showing positive effects on neurodegeneration biomarkers, with the greatest benefits observed in patients without Alzheimer’s disease co-pathology. The company is also advancing clinical development in ischemic stroke recovery and primary progressive aphasia.
Advertisement
ILAP Recognition Strengthens Global Development Strategy
The Innovation Passport adds another important regulatory milestone as CervoMed advances neflamapimod toward late-stage development for DLB. The company has previously aligned with the U.S. Food and Drug Administration (FDA) and other international regulators regarding a potential registration pathway and is actively seeking a strategic partner to support Phase 3 development. By securing participation in the UK’s ILAP program, CervoMed strengthens its global regulatory strategy while positioning neflamapimod for accelerated development in a disease area with substantial unmet medical need and no currently approved disease-modifying therapies.
Source: CervoMed,, press release
